Ranbaxy Ills Lead To Fears Among Other Indian Drug Makers
This article was originally published in PharmAsia News
Executive Summary
The allegations Ranbaxy Laboratories exported contaminated pharmaceuticals to the United States has brought increased scrutiny of all Indian drug makers by the U.S. FDA. Several of the dozen or more companies that supply drug ingredients to U.S. and European drug makers are concerned the suspicions will bring greater oversight by the drug makers themselves, delaying approvals and shipment clearances. The firms also are concerned about increased costs and added regulatory hurdles hampering their work. The CEO of Neuland said recent communications indicate the U.S. FDA and other U.S. agencies plan more stringent actions to ensure quality compliance and greater disclosure. (Click here for more